Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
Provided is a method of combination therapy for prevention or treatment of c-Met-induced or angiogenesis factor-induced diseases including co-administering an angiogenesis inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof to a patient.
1. A method for treatment of cancer metastasis, the method comprising co-administering (a) a VEGF antagonist and (b) an anti-c-Met antibody or antigen-binding fragment thereof to a subject in need thereof,
wherein the anti-c-Met antibody or the antigen-binding fragment thereof comprises:
a heavy chain variable region comprising a complementarity determining region (CDR)-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 22, 23, and 24; a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 25, and 26; and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 27, and 28; and
a light chain variable region comprising a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 29, 30, 31, 32, 33, and 106, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 34, 35, and 36, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 13, 14, 15, 16, and 37.
2. The method of claim 1 , wherein the angiogenesis inhibitor and the anti-c-Met antibody are administered simultaneously or sequentially in any order.
3. The method according to claim 1 , wherein the VEGF antagonist comprises at least one selected from the group consisting of bevacizumab, VEGF-trap, sunitinib, sunitinib malate, AEE-788, axitinib, AG-028262, combretastatin A4 analog, cediranib, BMS-387032, CEP-7055, CHIR-258, CP-547632, CP-564959, E-7080, Pazopanib, GW-654652, indazolylpyrimidine Kdr inhibitors, KRN-951, quinoline-urea VEGF inhibitors, midostaurin, vatalanib, anilinophthalazine derivative VEGF inhibitors, semaxanib, SU-6668, thalidomide, XL-647, XL-999, vandetanib, anilinoquinazoline VEGF inhibitors, ZK-304709, indirubin derivative VEGF inhibitors, CDP791, Enzastaurin, BIBF 1120, BAY 573952, BAY 734506, XL 184, IMC-1121B, CEP 701, SU 014813, SU 10944, SU 12662, OSI-930, BMS 582664, N-acetylcolchinol phosphate, ANG-400 series drugs, Imatinib, everolimus, and dasatinib.
4. The method according to claim 1 , wherein the anti c-Met antibody or the antigen-binding fragment thereof specifically binds to an epitope consisting of the amino acid sequence of SEQ ID NO: 71, 72, or 73.
5. The method according to claim 1 , wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 17, 74, 87, 90, 91, 92, 93, and 94, and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 18, 19, 20, 21, 75, 88, 95, 96, 97, 98, 99, 107, and 132.
6. The method according to claim 1 , wherein the anti c-Met antibody comprises:
a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, the amino acid sequence from the 18 th to 462 nd positions of SEQ ID NO: 62, the amino acid sequence from the 18 th to 461 st positions of SEQ ID NO: 64, and the amino acid sequence from the 18 th to 460 th positions of SEQ ID NO: 66, and
a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 108, the amino acid sequence from the 21 st to 240 th positions of SEQ ID NO: 68, and the amino acid sequence from the 21 st to 240 th positions of SEQ ID NO: 70.
7. The method according to claim 6 , wherein the anti c-Met antibody comprises:
a heavy chain comprising the amino acid sequence from the 18 th to 460 th positions of SEQ ID NO: 66, and
a light chain comprising the amino acid sequence from the 21 st to 240 th positions of SEQ ID NO: 68.
8. The method according to claim 1 , wherein the anti c-Met antibody is monoclonal.
9. The method according to claim 1 , wherein the anti c-Met antibody is an antibody of mouse origin, a mouse-human chimeric antibody, or a humanized antibody.
10. The method according to claim 1 , wherein the antigen-binding fragment is selected from the group consisting of scFv, (scFv) 2 , Fab, Fab′, and F(ab′) 2 .